Tugba A. Telli

Istanbul, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group.

Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group.

Journal: BMC cancer

Published: June 04, 2026

Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group.

Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group.

Journal: International journal of cancer

Published: July 31, 2025

Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations.

Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations.

Journal: Medicina (Kaunas, Lithuania)

Published: June 02, 2025

Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group.

Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group.

Journal: Clinical lung cancer

Published: May 01, 2025

The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey.

The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey.

Journal: Medicine

Published: November 14, 2023

Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer.

Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer.

Journal: Cancers

Published: October 30, 2023

The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study.

The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study.

Journal: International journal of cancer

Published: August 16, 2023

Standardized PSMA-PET Imaging of Advanced Prostate Cancer.

Standardized PSMA-PET Imaging of Advanced Prostate Cancer.

Journal: Seminars in nuclear medicine

Published: June 29, 2023

Prognostic value of Gustave Roussy immune score in operable pancreatic adenocarcinoma.

Prognostic value of Gustave Roussy immune score in operable pancreatic adenocarcinoma.

Journal: Indian journal of cancer

Published: March 02, 2023

Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters.

Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters.

Journal: Acta radiologica (Stockholm, Sweden : 1987)

Published: November 30, 2022

Prognostic significance of mucinous histology in left‑sided metastatic colorectal cancers with wild‑type RAS and evaluation of backbone chemotherapy regimens.

Prognostic significance of mucinous histology in left‑sided metastatic colorectal cancers with wild‑type RAS and evaluation of backbone chemotherapy regimens.

Journal: Oncology letters

Published: October 25, 2022

Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.

Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.

Journal: Future oncology (London, England)

Published: June 23, 2022

Showing 1-12 of 41

Last Updated: 09/26/2026